Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
Kathrin Heinrich(LMU Klinikum), Dominik Paul Modest(Berliner Hochschule für Technik), Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Alexander Koenig, Anke Reinacher‐Schick(Ruhr University Bochum), Annika Kurreck(Humboldt-Universität zu Berlin), Stefan Fruehauf(St. Marien Hospital), Annabel Helga Sophie Alig(Humboldt-Universität zu Berlin), Swantje Held(AIO Studien gGmbH), Ludwig von Weikersthal(Klinikum St. Marien Amberg), Ullrich Graeven(Kliniken Maria Hilf), Siegfried Haas(Friedrich-Ebert-Krankenhaus), Tanja Trarbach(Essen University Hospital), Karel Caca(Klinikum Ludwigsburg), Albrecht Kretzschmar(Roche (Switzerland)), Lothar Müller(Leibniz Centre for Agricultural Landscape Research), Eray Goekkurt(Sorbonne Université), Meinolf Karthaus(Evangelisches Krankenhaus Bielefeld), Arndt Stahler(Ludwig-Maximilians-Universität München)
Cited by 0
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k